{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Relapsed within the radiation treatment field","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.132","statisticalMethod":"Fisher Exact","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Relapsed inside thorax, outside of radiation field","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.337","statisticalMethod":"Fisher Exact","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Relapsed distant disease","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.457","statisticalMethod":"Fisher Exact","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.0","upperLimit":"45.2","value":"37.3"},{"groupId":"OG001","lowerLimit":"38.6","upperLimit":"53.2","value":"45.8"}]}],"title":"Relapsed within the radiation treatment field"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.6","upperLimit":"27.4","value":"20.5"},{"groupId":"OG001","lowerLimit":"11.4","upperLimit":"22.4","value":"16.3"}]}],"title":"Relapsed inside thorax, outside of radiation field"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.2","upperLimit":"57.8","value":"50.0"},{"groupId":"OG001","lowerLimit":"38.6","upperLimit":"53.2","value":"45.8"}]}],"title":"Relapsed distant disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"190"}],"units":"Participants"}],"description":"The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles","id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT"},{"description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22","id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT"}],"paramType":"NUMBER","populationDescription":"All randomized participants with objective PD.","reportingStatus":"POSTED","timeFrame":"Baseline to Relapse (Up to 66.6 Months)","title":"First Site of Disease Failure in Terms of Relapse","type":"SECONDARY","unitOfMeasure":"percentage of participants"}